Marcel Klingenberg
YOU?
Author Swipe
View article: Supplementary Figure 1 from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma
Supplementary Figure 1 from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma Open
PDF - 1109K, Blood and lymphatic vessel density in experimental BL2B95 tumors treated with IB in the CAM model.
View article: Data from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma
Data from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma Open
Burkitt lymphoma is a rare malignancy arising from B cells. Current chemotherapeutic regimens achieve excellent overall survival rates in children, but less impressive rates in adults. There are cases with poor outcome caused by toxic effe…
View article: Supplementary Figure 1 from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma
Supplementary Figure 1 from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma Open
PDF - 1109K, Blood and lymphatic vessel density in experimental BL2B95 tumors treated with IB in the CAM model.
View article: Data from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma
Data from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma Open
Burkitt lymphoma is a rare malignancy arising from B cells. Current chemotherapeutic regimens achieve excellent overall survival rates in children, but less impressive rates in adults. There are cases with poor outcome caused by toxic effe…
View article: Challenges of CRISPR/Cas9 applications for long non-coding RNA genes
Challenges of CRISPR/Cas9 applications for long non-coding RNA genes Open
The CRISPR/Cas9 system provides a revolutionary genome editing tool for all areas of molecular biology. In long non-coding RNA (lncRNA) research, the Cas9 nuclease can delete lncRNA genes or introduce RNA-destabilizing elements into their …